Robotic-Assisted Aneurysm Embolization Achieves 94% Technical Success Rate in Six-Month Follow-Up Study
Key Insights
The CorPath GRX (search) robotic system demonstrated a 94% technical success rate in neuroendovascular aneurysm embolization across 117 patients in an international multicenter trial.
Complete aneurysm occlusion rates improved significantly from 64.5% immediately post-procedure to 94.1% at six-month follow-up.
Favorable clinical outcomes were observed in 98.9% of patients at six months, representing the first published mid-term data for robotic-assisted neuroendovascular aneurysm treatment.
The first comprehensive six-month follow-up data from a pioneering robotic-assisted neuroendovascular aneurysm embolization trial has demonstrated promising safety and effectiveness outcomes, with researchers achieving a 94% technical success rate using the CorPath GRX (search) system. The results were presented by Vitor Pereira, MD, at the Society of NeuroInterventional Surgery (search)'s 22nd Annual Meeting, representing a significant milestone as the only published mid-term clinical follow-up data to date on robotic-assisted neuroendovascular aneurysm embolization.
Study Design and Scope
The prospective, single-arm, international, multicenter, non-inferiority study enrolled 117 patients across 10 clinical sites, conducted by 14 neurointerventionalists spanning six countries. The comprehensive trial included both a premarket study in Canada and post-market studies in Australia, Austria, France, Spain, and Switzerland, providing robust international validation of the robotic technology.
Clinical Outcomes and Effectiveness
The study achieved its primary effectiveness endpoint, defined as successful completion of the robotic-assisted neuroendovascular procedure without unplanned conversions to manual intervention, in 94% of cases. This technical success rate demonstrates the reliability of robotic assistance in complex neuroendovascular procedures.
Particularly notable was the improvement in complete aneurysm occlusion rates over time. While immediate complete occlusion (RROC 1) was achieved in 64.5% of patients, this rate increased substantially to 94.1% at the six-month follow-up, indicating continued therapeutic benefit and aneurysm healing over time.
Patient Safety and Functional Outcomes
The safety profile of robotic-assisted aneurysm embolization proved favorable, with 98.9% of patients (87 out of 88) achieving favorable clinical outcomes as measured by modified Rankin Scale scores of 0-2 at six months. This high rate of good functional outcomes suggests that the robotic approach maintains patient safety while potentially offering procedural advantages.
Clinical Significance and Future Implications
"The six-month results of the CorPath GRX (search) trial represent a significant step forward in the evolution of neuroendovascular robotics and will play a key role in shaping future innovation in the field of neuroendovascular therapy," said Dr. Pereira. "It shows that robotics in neuroendovascular interventions could provide precision and support to the physician even in navigating tortuous anatomy and treatment of complex aneurysm cases."
The trial was sponsored by Siemens Healthineers (search) Endovascular Robotics, Inc., which continues to invest in the development of their next-generation neuroendovascular robotic platform. These results provide crucial evidence for the potential integration of robotic assistance into standard neuroendovascular practice, particularly for complex aneurysm cases that require precise navigation through challenging vascular anatomy.